AU2008335324A1 - Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome - Google Patents

Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome Download PDF

Info

Publication number
AU2008335324A1
AU2008335324A1 AU2008335324A AU2008335324A AU2008335324A1 AU 2008335324 A1 AU2008335324 A1 AU 2008335324A1 AU 2008335324 A AU2008335324 A AU 2008335324A AU 2008335324 A AU2008335324 A AU 2008335324A AU 2008335324 A1 AU2008335324 A1 AU 2008335324A1
Authority
AU
Australia
Prior art keywords
meganuclease
group
sense strand
modification
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008335324A
Other languages
English (en)
Inventor
Derek Jantz
Michael G. Nicholson
James Jefferson Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biosciences Inc
Original Assignee
Precision Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biosciences Inc filed Critical Precision Biosciences Inc
Publication of AU2008335324A1 publication Critical patent/AU2008335324A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008335324A 2007-12-07 2008-12-08 Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome Abandoned AU2008335324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US568607P 2007-12-07 2007-12-07
US61/005,686 2007-12-07
PCT/US2008/085878 WO2009076292A2 (en) 2007-12-07 2008-12-08 Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome

Publications (1)

Publication Number Publication Date
AU2008335324A1 true AU2008335324A1 (en) 2009-06-18

Family

ID=40756084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008335324A Abandoned AU2008335324A1 (en) 2007-12-07 2008-12-08 Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome

Country Status (6)

Country Link
US (2) US20110033935A1 (enExample)
EP (1) EP2215252A4 (enExample)
JP (1) JP2011505809A (enExample)
AU (1) AU2008335324A1 (enExample)
CA (1) CA2703079A1 (enExample)
WO (1) WO2009076292A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036640A2 (en) * 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
EP2504429B1 (en) 2009-11-27 2016-04-20 BASF Plant Science Company GmbH Chimeric endonucleases and uses thereof
DE112010004582T5 (de) 2009-11-27 2012-11-29 Basf Plant Science Company Gmbh Optimierte Endonukleasen und Anwendungen davon
JP2013511979A (ja) 2009-11-27 2013-04-11 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
WO2011095475A1 (en) * 2010-02-02 2011-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and therapy of retinitis pigmentosa
ES2713529T3 (es) 2011-06-01 2019-05-22 Prec Biosciences Inc Procedimientos y productos para la producción de líneas celulares de mamífero modificadas con transgenes amplificados
US9758796B2 (en) 2011-06-10 2017-09-12 Basf Plant Science Company Gmbh Nuclease fusion protein and uses thereof
EP2790708B1 (en) 2011-12-16 2024-10-23 Targetgene Biotechnologies Ltd. Compositions and methods for modifying a predetermined target nucleic acid sequence
EP2612918A1 (en) 2012-01-06 2013-07-10 BASF Plant Science Company GmbH In planta recombination
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
MX2020003838A (es) 2017-10-13 2020-08-06 Selecta Biosciences Inc Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral.
KR20200139679A (ko) 2018-02-26 2020-12-14 안톨알엑스, 인크. 면역관용성 리포솜 및 그의 사용 방법
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5792640A (en) * 1992-04-03 1998-08-11 The Johns Hopkins University General method to clone hybrid restriction endonucleases using lig gene
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5792632A (en) * 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5474896A (en) * 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) * 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5830729A (en) * 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US6265196B1 (en) * 1996-05-07 2001-07-24 Johns Hopkins University Methods for inactivating target DNA and for detecting conformational change in a nucleic acid
JP2002535995A (ja) * 1999-02-03 2002-10-29 ザ チルドレンズ メディカル センター コーポレイション 染色体標的部位での二本鎖dna切断の誘導を含む遺伝子修復
WO2000046385A1 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting dna
US6794136B1 (en) * 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
US7314712B2 (en) * 2001-07-27 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
AU2003251286B2 (en) * 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
AU2003215869B2 (en) * 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
JP2006502748A (ja) * 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
US7285699B2 (en) * 2002-10-07 2007-10-23 Stowers Institute For Medical Research Ends-out gene targeting method
US20030175968A1 (en) * 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
AU2004208031B2 (en) * 2003-01-28 2009-10-08 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ATE514782T1 (de) * 2003-11-18 2011-07-15 Bayer Bioscience Nv Verbesserte gezielte dna insertion in pflanzen
WO2006097875A1 (en) * 2005-03-14 2006-09-21 Koninklijke Philips Electronics N.V. Method of producing a component with a surface structure, ceramic component and application of such a method
EP2650366B1 (en) * 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof

Also Published As

Publication number Publication date
US20110033935A1 (en) 2011-02-10
JP2011505809A (ja) 2011-03-03
WO2009076292A3 (en) 2010-01-07
EP2215252A2 (en) 2010-08-11
EP2215252A4 (en) 2011-01-26
CA2703079A1 (en) 2009-06-18
WO2009076292A2 (en) 2009-06-18
US20130224863A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
US20240228994A9 (en) Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US20130224863A1 (en) Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted